Literature DB >> 6149270

Bradykinin receptor-mediated cyclic GMP formation in a nerve cell population (murine neuroblastoma clone N1E-115).

R M Snider, E Richelson.   

Abstract

A clone of murine neuroblastoma (N1E-115) was shown to have functional receptors for the nonapeptide bradykinin. These receptors mediated a large, rapid (about 1 min to peak) and calcium-dependent increase in cyclic GMP. The median effective concentration (EC50) averaged 1.4 nM. In addition, this event was inhibited by quinacrine, 5,8,11,14-eicosatetraynoic acid, and nordi-hydroguaiaretic acid, suggesting involvement of phospholipase A2 with subsequent formation of lipoxygenase metabolities of arachidonic acid. [3H]Bradykinin binding to intact cells, investigated under conditions nearly identical to those used in the cyclic GMP assay, yielded binding sites with KDS of 0.83 pM, 1.0 nM, and 4.9 nM with respective Bmax values of 12, 160, and 250 fmol/10(6) cells. Apparently, the cyclic GMP response was associated with the binding site in which the KD = 1.0 nM. Peptide analogs of bradykinin stimulated cyclic GMP with EC50S nearly identical to their respective KDS determined in binding assays with [3H]bradykinin, thus providing evidence for receptor specificity of this response. This finding of a biochemical response of bradykinin promises to make N1E-115 cells a convenient model system for study of neuronal bradykinin receptors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149270     DOI: 10.1111/j.1471-4159.1984.tb06104.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  11 in total

1.  Bradykinin analogues: differential agonist and antagonist activities suggesting multiple receptors.

Authors:  K M Braas; D C Manning; D C Perry; S H Snyder
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

2.  An image-based model of calcium waves in differentiated neuroblastoma cells.

Authors:  C C Fink; B Slepchenko; I I Moraru; J Watras; J C Schaff; L M Loew
Journal:  Biophys J       Date:  2000-07       Impact factor: 4.033

3.  Bradykinin causes a transient rise of intracellular Ca2+-activity in cultured neural cells.

Authors:  G Reiser; B Hamprecht
Journal:  Pflugers Arch       Date:  1985-10       Impact factor: 3.657

4.  The neuropeptide bradykinin stimulates phosphoinositide turnover in HSDM1C1 cells: B2-antagonist-sensitive responses and receptor binding studies.

Authors:  N A Sharif; R L Whiting
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

5.  Human bradykinin B2 receptors isolated by receptor-specific monoclonal antibodies are tyrosine phosphorylated.

Authors:  Y J Jong; L R Dalemar; B Wilhelm; N L Baenziger
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

6.  The effects of phorbol ester on slowly conducting afferents of the cat's knee joint.

Authors:  K Schepelmann; K Messlinger; R F Schmidt
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

7.  Lithium ions inhibit function of low- but not high-affinity muscarinic receptors of murine neuroblastoma cells (clone N1E-115).

Authors:  S Kanba; M Pfenning; E Richelson
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Endothelin and a Ca2+ ionophore raise cyclic GMP levels in a neuronal cell line via formation of nitric oxide.

Authors:  G Reiser
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

9.  Serine-727 phosphorylation activates hypothalamic STAT-3 independently from tyrosine-705 phosphorylation.

Authors:  Andreas Breit; Valeria Besik; Hans Jürgen Solinski; Susanne Muehlich; Evi Glas; Stephen J Yarwood; Thomas Gudermann
Journal:  Mol Endocrinol       Date:  2015-01-13

10.  Receptor coupled events in bradykinin action: rapid production of inositol phosphates and regulation of cytosolic free Ca2+ in a neural cell line.

Authors:  T R Jackson; T J Hallam; C P Downes; M R Hanley
Journal:  EMBO J       Date:  1987-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.